Stockreport

Mateon Expands its COVID-19 Therapeutic Program to include Artemisinin

MATEON THERAPEUTICS  (MATN) 
Last mateon therapeutics earnings: 11/19 05:25 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.mateon.com
PDF In vitro data generated by the company and its collaborators supports the ability of artemisinin, an anti-malarial drug, to inhibit SARS-CoV-2 which can lead to COVID-19 [Read more]